Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1995 Aug;50(8):834–837. doi: 10.1136/thx.50.8.834

Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease.

P Moayyedi 1, J Congleton 1, R L Page 1, S B Pearson 1, M F Muers 1
PMCID: PMC474895  PMID: 7570433

Abstract

BACKGROUND--Patients admitted with acute exacerbation of chronic obstructive pulmonary disease (COPD) are often prescribed ipratropium bromide in combination with a beta 2 agonist such as salbutamol. Studies have not shown any benefit in adding ipratropium bromide to salbutamol in acute exacerbations of COPD, but these studies have only assessed patients for 60-90 minutes and short term studies may not predict long term clinical response. Combination therapy with the two drugs was compared with salbutamol alone in the treatment of acute exacerbations of COPD during a hospital admission. METHODS--Seventy patients admitted to hospital with an acute exacerbation of COPD were randomly allocated to receive either nebulised salbutamol 5 mg and ipratropium bromide 500 micrograms, or nebulised salbutamol 5 mg alone (all four times a day) on admission. All other treatment was prescribed at the discretion of the attending physician. Length of stay in hospital and spirometric values on days 1, 3, 7, 14, and discharge were assessed. Patients completed a subjective symptom score each day. RESULTS--There was no difference between the two groups in the mean (SD) length of stay (salbutamol 10.5 (4.7) days, salbutamol + ipratropium bromide 11.8 (4.4) days; 95% CI -1.02 to 3.62). There was no difference in spirometric values on days 1, 3, 7, 14, or discharge between the two groups. The subjective improvement was similar with both treatments. CONCLUSIONS--The routine addition of nebulised ipratropium bromide to salbutamol appears to be of no benefit in the treatment of acute exacerbations of COPD.

Full text

PDF
834

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALTOUNYAN R. E. VARIATION OF DRUG ACTION ON AIRWAY OBSTRUCTION IN MAN. Thorax. 1964 Sep;19:406–415. doi: 10.1136/thx.19.5.406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Braun S. R., McKenzie W. N., Copeland C., Knight L., Ellersieck M. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Arch Intern Med. 1989 Mar;149(3):544–547. [PubMed] [Google Scholar]
  3. Brown I. G., Chan C. S., Kelly C. A., Dent A. G., Zimmerman P. V. Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation. Thorax. 1984 Apr;39(4):272–276. doi: 10.1136/thx.39.4.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Connolly C. K., Chan N. S. Salbutamol and ipratropium in partially reversible airway obstruction. Br J Dis Chest. 1987 Jan;81(1):55–61. doi: 10.1016/0007-0971(87)90108-2. [DOI] [PubMed] [Google Scholar]
  5. Crane J., Gamble S., Purdie G. Comparison of a fenoterol/ipratropium combination with salbutamol from metered dose inhalers in subjects with chronic partially reversible airways obstruction. N Z Med J. 1987 Jun 24;100(826):385–387. [PubMed] [Google Scholar]
  6. Easton P. A., Jadue C., Dhingra S., Anthonisen N. R. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med. 1986 Sep 18;315(12):735–739. doi: 10.1056/NEJM198609183151205. [DOI] [PubMed] [Google Scholar]
  7. Goldman J. M., Teale C., Muers M. F. Simplifying the assessment of patients with chronic airflow limitation for home nebulizer therapy. Respir Med. 1992 Jan;86(1):33–38. doi: 10.1016/s0954-6111(06)80145-9. [DOI] [PubMed] [Google Scholar]
  8. Gross N. J., Skorodin M. S. Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis. 1984 May;129(5):856–870. doi: 10.1164/arrd.1984.129.5.856. [DOI] [PubMed] [Google Scholar]
  9. Gross N. J., Skorodin M. S. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med. 1984 Aug 16;311(7):421–425. doi: 10.1056/NEJM198408163110701. [DOI] [PubMed] [Google Scholar]
  10. Guyatt G. H., Berman L. B., Townsend M., Pugsley S. O., Chambers L. W. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987 Oct;42(10):773–778. doi: 10.1136/thx.42.10.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Guyatt G. H., Berman L. B., Townsend M., Pugsley S. O., Chambers L. W. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987 Oct;42(10):773–778. doi: 10.1136/thx.42.10.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hughes J. A., Tobin M. J., Bellamy D., Hutchison D. C. Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema. Thorax. 1982 Sep;37(9):667–670. doi: 10.1136/thx.37.9.667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jenkins C. R., Chow C. M., Fisher B. L., Marlin G. E. Comparison of ipratropium bromide and salbutamol by aerosolized solution. Aust N Z J Med. 1981 Oct;11(5):513–516. doi: 10.1111/j.1445-5994.1981.tb04621.x. [DOI] [PubMed] [Google Scholar]
  14. Jones P. W., Quirk F. H., Baveystock C. M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992 Jun;145(6):1321–1327. doi: 10.1164/ajrccm/145.6.1321. [DOI] [PubMed] [Google Scholar]
  15. Mahler D. A., Weinberg D. H., Wells C. K., Feinstein A. R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984 Jun;85(6):751–758. doi: 10.1378/chest.85.6.751. [DOI] [PubMed] [Google Scholar]
  16. Morrison J. F., Jones P. C., Muers M. F. Assessing physiological benefit from domiciliary nebulized bronchodilators in severe airflow limitation. Eur Respir J. 1992 Apr;5(4):424–429. [PubMed] [Google Scholar]
  17. O'Driscoll B. R., Kay E. A., Taylor R. J., Weatherby H., Chetty M. C., Bernstein A. A long-term prospective assessment of home nebulizer treatment. Respir Med. 1992 Jul;86(4):317–325. doi: 10.1016/s0954-6111(06)80031-4. [DOI] [PubMed] [Google Scholar]
  18. O'Driscoll B. R., Taylor R. J., Horsley M. G., Chambers D. K., Bernstein A. Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet. 1989 Jun 24;1(8652):1418–1420. doi: 10.1016/s0140-6736(89)90126-8. [DOI] [PubMed] [Google Scholar]
  19. Pineda H., Haas F., Axen K., Haas A. Accuracy of pulmonary function tests in predicting exercise tolerance in chronic obstructive pulmonary disease. Chest. 1984 Oct;86(4):564–567. doi: 10.1378/chest.86.4.564. [DOI] [PubMed] [Google Scholar]
  20. Pratter M. R., Irwin R. S. Predicting response to bronchodilator therapy in chronic obstructive pulmonary disease. Arch Intern Med. 1988 Sep;148(9):1909–1910. [PubMed] [Google Scholar]
  21. Rebuck A. S., Chapman K. R., Abboud R., Pare P. D., Kreisman H., Wolkove N., Vickerson F. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med. 1987 Jan;82(1):59–64. doi: 10.1016/0002-9343(87)90378-0. [DOI] [PubMed] [Google Scholar]
  22. Rudolf M. Combination therapy--a review of clinical studies. Postgrad Med J. 1984;60 (Suppl 1):9–12. [PubMed] [Google Scholar]
  23. Taylor D. R., Buick B., Kinney C., Lowry R. C., McDevitt D. G. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis. 1985 May;131(5):747–751. doi: 10.1164/arrd.1985.131.5.747. [DOI] [PubMed] [Google Scholar]
  24. Teale C., Morrison J. F., Jones P. C., Muers M. F. Reversibility tests in chronic obstructive airways disease: their predictive value with reference to benefit from domiciliary nebuliser therapy. Respir Med. 1991 Jul;85(4):281–284. doi: 10.1016/s0954-6111(06)80097-1. [DOI] [PubMed] [Google Scholar]
  25. Teale C., Morrison J. F., Muers M. F., Pearson S. B. Response to nebulized ipratropium bromide and terbutaline in acute severe asthma. Respir Med. 1992 May;86(3):215–218. doi: 10.1016/s0954-6111(06)80058-2. [DOI] [PubMed] [Google Scholar]
  26. Ward M. J., Fentem P. H., Smith W. H., Davies D. Ipratropium bromide in acute asthma. Br Med J (Clin Res Ed) 1981 Feb 21;282(6264):598–600. doi: 10.1136/bmj.282.6264.598. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES